from the world's big
Can Limits On Extreme Wealth End Poverty?
With the global income gap continuing to widen, Oxfam International releases a statement that focuses on the rich rather than the poor.
What's the Latest Development?
Last week, Oxfam International released a statement titled "The cost of inequality: how wealth and extreme incomes hurt us all." In it, the anti-poverty organization cites the World Economic Forum's recent report labeling "severe income disparity" as one of the top global risks for 2013, and offers several suggestions for curtailing wealth accumulation, including closing tax havens worldwide, setting a global minimum corporate tax rate, and limiting the size of bonuses. The goal, the report says, is "to end extreme wealth by 2025."
What's the Big Idea?
Rather than focusing on uplifting the poor through jobs and services, Oxfam's statement addresses growing concern around the world about the ultra-rich "1 percent." According to the organization, the top 100 billionaires earned enough money in 2012 "to end world poverty four times over." While some of these billionaires, including Bill Gates, provide a great deal of aid, the growing economic gap between rich and poor won't be alleviated unless extreme measures are taken. The real challenge lies with governments "willing to risk angering their wealthiest citizens in order to improve life for the poorest."
Photo Credit: Shutterstock.com
What would it be like to experience the 4th dimension?
Physicists have understood at least theoretically, that there may be higher dimensions, besides our normal three. The first clue came in 1905 when Einstein developed his theory of special relativity. Of course, by dimensions we’re talking about length, width, and height. Generally speaking, when we talk about a fourth dimension, it’s considered space-time. But here, physicists mean a spatial dimension beyond the normal three, not a parallel universe, as such dimensions are mistaken for in popular sci-fi shows.
Vaccines find more success in development than any other kind of drug, but have been relatively neglected in recent decades.
Vaccines are more likely to get through clinical trials than any other type of drug — but have been given relatively little pharmaceutical industry support during the last two decades, according to a new study by MIT scholars.
Sallie Krawcheck and Bob Kulhan will be talking money, jobs, and how the pandemic will disproportionally affect women's finances.
An article in Journal of Bioethical Inquiry raises questions about the goal of these advocacy groups.